Correlation found between change in IOP and conjunctival hyperaemia induced by latanoprost

Article

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study.

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study published in the Journal of Glaucoma.

Drs Hiroshi and Kaori Kobayashi, from Amagasaki Hospital, Hyogo and Osaka Red Cross Hospital, Osaka, Japan, respectively, examined 114 patients with open-angle glaucoma or ocular hypertension. Their aim was to determine any correlation between a short-term change in conjunctival hyperaemia severity and the IOP-reducing effect induced by latanoprost.

Of the 114 patients 56 were female and 58 were male and they had a mean age of 60.9±15 years. The primary outcome of the study was to determine the change in conjunctival hyperaemia grade at day 2 and the change in IOP at 6 months after commencing latanoprost treatment.

The mean IOP before latanoprost treatment was 22.5±3.8 mmHg and after 6 months it was 16.5±2.9 mmHg (P < 0.0001). Mean changes in conjunctival hyperaemia before and after 2 days of latanoprost treatment were 0.32±0.58 and 1.74±1.11, respectively (P < 0.0001). It was found that the mean change in IOP was greater in eyes with a higher hyperaemia grade change.

In conclusion, the researchers found a significant correlation between the change in IOP and the conjunctival hyperaemia severity after treatment with latanoprost.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.